目的 评估经导管动脉化疗栓塞(TACE)和射频消融(RFA)术后序贯联合细胞因子诱导杀伤(CIK)细胞治疗早期肝癌的安全性和有效性.方法 回顾性分析2001年6月至2012年1月在中山大学肿瘤防治中心行TACE联合RFA治疗的早期肝癌患者(共63例).将联合CIK回输治疗的患者分为TACE+ RFA+ CIK组(共31例),其余为TACE+ RFA组(共32例),并对比分析两组的总生存期(OS)、无进展生存期(PFS)及不良反应.结果 TACE+ RFA+ CIK组的中位OS及PFS优于TACE+ RFA组,且差异有统计学意义(OS:107.5和61.4个月,P=0.038;PFS:43.0和30.0个月,P =0.024).TACE+ RFA+ CIK组3、5、10年总生存率均高于TACE+ RFA组(93.3%、77.7%和35.4%比76.7%、57.7%、29.3%).同时,TACE+RFA+CIK组1、3、5年无进展生存率均高于TACE+ RFA组(93.5%、66.4%和28.4%比84.4%、38.5%和0.1%).两组均未观察到严重并发症.结论 CIK细胞免疫治疗安全、可行,有助于延长早期肝癌的总生存期和无进展生存期.
Objective To evaluate the safety and efficiency of transcatheter arterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) combined with cytokineinduced killer (CIK) cells transfusion for early-stage hepatocellular carcinoma (HCC).Methods A retrospective analysis was conducted for 63 early-stage HCC patients who were treated with TACE and sequential RFA in this hospital between July 2001 and January 2012.These patients were divided into two groups:TACE + RFA + CIK (31 patients) and TACE + RFA (32 patients).Overall survival (OS),progression-free survival (PFS) and adverse events were compared between two groups.Results The median OS and PFS in the TACE + RFA + CIK group were significantly longer than those in TACE + RFA group (OS:107.5 vs 61.4 months,respectively,P =0.038 ; PFS:43.0 vs 30.0 months respectively,P =0.024).The 3-,5-and 10-year cumulative overall survival rates in the TACE + RFA + CIK group were higher than those in the TACE + RFA group (93.3%,77.7% and 35.4% vs 76.7%,57.7% and 29.3%,respectively).The 1-,3-,and 5-year cumulative progression-free survival rates were also higher in the TACE + RFA + CIK group (93.5%,66.4% and 28.4% vs 84.4%,38.5% and 0.1%,respectively).No serious complications were observed in both groups.Conclusion This study suggests that CIK cells transfusion is safe,feasible,and superior in prolonging the OS and PFS time of early-stage HCC.However,any conclusions must be confirmed by more clinical studies.